Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Chief Human Resources Officer | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,431.071 |
Ending reported balance
After 2026-03-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-31 · Exercise / conversion · Acquired 6,732 · Balance 96,378.071 Row 2 · 2026-03-31 · Tax withholding · Disposed 2,306 · Balance 94,072.071 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 11,193 · Balance 105,265.071 Row 4 · 2026-03-31 · Tax withholding · Disposed 3,834 · Balance 101,431.071 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 166,944 |
Reported balance
After 2026-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-31 · Grant · Acquired 166,944 · Balance 166,944 F2: On March 31, 2026, the Reporting Person was granted 166,944 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-31 · Exercise / conversion · Disposed 6,732 · Balance 0 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F4: On March 31, 2023, the Reporting Person was granted 20,195 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 22,386 |
Reported balance
After 2026-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-31 · Exercise / conversion · Disposed 11,193 · Balance 22,386 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2025, the Reporting Person was granted 33,579 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining to vest on March 31, 2027 and March 31, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2: On March 31, 2026, the Reporting Person was granted 166,944 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F3: Each RSU represents a contingent right to receive one share of Organon common stock.
F4: On March 31, 2023, the Reporting Person was granted 20,195 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
F5: On March 31, 2025, the Reporting Person was granted 33,579 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining to vest on March 31, 2027 and March 31, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2023 Filed May 3, 2023 23:05 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 419 | $24.63 | $10,319.97 |
DisclosureSEC source: 0001209191-23-027171 · doc4.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,941 Read SEC document |
| May 01, 2023 Filed May 3, 2023 23:05 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,221 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-027171 · doc4.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 72,519 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · derivative · entry 5 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,519 Underlying: Common Stock · 72,519 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 20,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · derivative · entry 4 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,195 Underlying: Common Stock · 20,195 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,157 Underlying: Common Stock · 3,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,226 | $23.09 | $28,308.34 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,139 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:22 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 5,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014825 · doc4.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,125 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:22 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,901 | $25.09 | $47,696.09 |
DisclosureSEC source: 0001209191-23-014825 · doc4.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,787 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:22 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 5,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014825 · doc4.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 2,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056626 · tm2214603-2_4seq1.xml · derivative · entry 6 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,770 Underlying: Common Stock · 2,770 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. F2 · derivative.expiration_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:46 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 949 | $32.44 | $30,785.56 |
DisclosureSEC source: 0001104659-22-056626 · tm2214603-2_4seq1.xml · nonDerivative · entry 4 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,563 Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 2,770 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056626 · tm2214603-2_4seq1.xml · nonDerivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 03, 2022 Filed May 6, 2022 00:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 871 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056626 · tm2214603-2_4seq1.xml · derivative · entry 5 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871 Underlying: Common Stock · 871 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 03, 2022 Filed May 6, 2022 00:46 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 299 | $32.08 | $9,591.92 |
DisclosureSEC source: 0001104659-22-056626 · tm2214603-2_4seq1.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,742 Read SEC document |
| May 03, 2022 Filed May 6, 2022 00:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 871 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056626 · tm2214603-2_4seq1.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055427 · tm2214297-2_4seq1.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219 Underlying: Common Stock · 1,219 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 418 | $32.33 | $13,513.94 |
DisclosureSEC source: 0001104659-22-055427 · tm2214297-2_4seq1.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,170 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055427 · tm2214297-2_4seq1.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:04 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 33,068 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042354 · tm2211465-2_4seq1.xml · derivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,068 Underlying: Common Stock · 33,068 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:04 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 10,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042354 · tm2211465-2_4seq1.xml · derivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,735 Underlying: Common Stock · 10,735 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029451 · tm228175-1_4seq1.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,795 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:43 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,727 | $37.57 | $64,883.39 |
DisclosureSEC source: 0001104659-22-029451 · tm228175-1_4seq1.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,369 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029451 · tm228175-1_4seq1.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:00 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033656 · doc4.xml · derivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 64,433 | $0.00 Strike: $36.11 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 10 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,433 Underlying: Common Stock · 64,433 shares Expires 2031-05-03 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 28,611 | $0.00 Strike: $36.91 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 9 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,611 Underlying: Common Stock · 28,611 shares Expires 2030-04-30 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F11 · derivative.exercise_date: 9,537 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 19,606 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 8 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,606 Underlying: Common Stock · 19,606 shares Expires 2029-05-02 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F10 · derivative.exercise_date: 13,071 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 11,015 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 7 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,015 Underlying: Common Stock · 11,015 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 5,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 6 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,125 Underlying: Common Stock · 5,125 shares Expires 2022-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 4,794 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 5 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,794 Underlying: Common Stock · 4,794 shares Expires 2021-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 8,310 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 4 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,310 Underlying: Common Stock · 8,310 shares Expires 2024-05-04 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 2,440 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,440 Underlying: Common Stock · 2,440 shares Expires 2023-05-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 871 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871 Underlying: Common Stock · 871 shares Expires 2022-05-03 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.